Project

Go Back to Project List
#18275 : scRNAseq analysis of Tumor-Infiltrating ILCs
Topics: Single Cells (GEX/ATAC/ADT/Multiome…)
Origin: IP
Project type: Service

Name of Applicant: Nicolas SERAFINI
Date of application: 14-05-2024
Unit: Innate Immunity
Location: 67-4-4050
Phone: 0140613212
@ Mail: nicolas.serafini@pasteur.fr
@ PI-Mail: james.di-santo@pasteur.fr

Project context and summary:

The presence and fate of tumor-infiltrating immune cells, which exert pressure on tumor cells and have prognostic value, can be altered by the inflammatory microenvironment. While the innate immune response is the first line of defense against pathogens, it can also induce disorders and chronic pathologies and correlate with tumor development, which can be facilitated by aberrant immune responses or environmental factors. Innate lymphoid cells are tissue-resident lymphocytes that promote mucosal homeostasis and immunity. In contrast, the surveillance behavior of ILCs in intestinal tumorigenesis is largely unknown. Here, we investigate the role of intestinal ILCs in tumor progression. Using a single cell RNAseq approach, we plan to perform a transcriptional profiling analysis of tumor-infiltrating ILCs.


Related team publications:
Group 3 innate lymphoid cells: A trained Gutkeeper. Serafini N, Di Santo JP. Immunol Rev. 2024
Inflammation triggers ILC3 patrolling of the intestinal barrier. Jarade A, Garcia Z, Marie S, Demera A, Prinz I, Bousso P, Di Santo JP, Serafini N. Nat Immunol. 2022
Trained ILC3 responses promote intestinal defense. Serafini N, Jarade A, Surace L, Goncalves P, Sismeiro O, Varet H, Legendre R, Coppee JY, Disson O, Durum SK, Frankel G, Di Santo JP. Science. 2022
Service Delivery
Manager: marc.monot@pasteur.fr
Status: Sequencing


Go Back to Project List